The aim of the present study has been, on the one hand, to describe the characteristics and outcome of an unselected population of diabetics undergoing percutaneous revascularization and, on the other hand, to analyze the factors predictive of complications in the follow-up period. Previous studies have reported prognosis in relation to treatment with or without insulin, and not to the type of diabetes. Median patient age was 71 years and median follow-up was 26.5 months. We analyzed data from a cohort, the Nord-Trøndelag Health Study (HUNT study) linked to the Norwegian Cancer Registry and controlled the results using two lung cancer studies, the Pemetrexed Gemcitabine study and the Norwegian Lung Cancer Biobank. Resting blood pressure and BMI were recorded at randomization. Among the group of diabetics, 43.4% were on insulin therapy, 37.1% were receiving oral antidiabetic therapy, and 19.5% were managed by diet. The most accurate cut-point in both the N-R group (87%) and R group (61%) was 120 pg/ml of BNP.
CONCLUSION: DM status could be a prognostic factor for OSCC, particularly for its effect in the survival and perineural invasion. 91.5%; OS: 73.9% vs. 87.9%). After adjusting for clinicopathologic variables and comorbidities, DM remained an independent unfavorable prognostic factor for CSS (adjusted HR: 1.46) and OS (adjusted HR: 1.55). Type 2 diabetes mellitus (DM) increases the incidence of several types of cancer but not cervical cancer (CC); however, less is known about the impact of DM on patients who already have CC. Surveillance of diabetes status and antidiabetes medication administration after the diagnosis of PC is of clinical importance. Incorporating DM control should be considered part of the continuum of care for early stage CC patients, and close surveillance during routine follow-up in this population is recommended.